JFDA affirms effectiveness of AstraZeneca COVID vaccine

AMMAN — The AstraZeneca vaccine showed efficacy in reducing hospital admissions and COVID-19 fatalities, the Jordan Food and Drug Administration (JFDA) said on Thursday. 

JFDA Director General Nizar Mheidat, in a statement, said that a total of 144,000 AstraZeneca jabs have been administered in Jordan and no unexpected side effects have been reported. He stressed that all medical notes reported after administering the AstraZeneca vaccine were common side effects “with nothing unusual”, the Jordan News Agency, Petra, reported.

The UK, Australia, Italy, France, Spain, Portugal, among others, continue using the AstraZeneca COVID-19 vaccine, as the rate of blood clotting following vaccination with AstraZeneca's COVID-19 vaccine does not exceed 0.0000015 per cent, a tiny percentage that does not necessitate the suspension of the vaccine, Mheidat added.